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Abstract
Subtype-selective ligands are important tools for the pharmacological characterisation of neurotransmitter receptors. This is
particularly the case for nicotinic acetylcholine receptors (nAChRs), given the heterogeneity of their subunit composition. In
addition to agonists and antagonists that interact with the extracellular orthosteric nAChR binding site, a series of nAChR
allosteric modulators have been identified that interact with a distinct transmembrane site. Here we report studies
conducted with three pharmacologically distinct nicotinic ligands, an orthosteric agonist (compound B), a positive allosteric
modulator (TQS) and an allosteric agonist (4BP-TQS). The primary focus of the work described in this study is to examine the
suitability of these compounds for the characterisation of native neuronal receptors (both rat and human). However, initial
experiments were conducted on recombinant nAChRs demonstrating the selectivity of these three compounds for a7
nAChRs. In patch-clamp recordings on rat primary hippocampal neurons we found that all these compounds displayed
pharmacological properties that mimicked closely those observed on recombinant a7 nAChRs. However, it was not possible
to detect functional responses with compound B, an orthosteric agonist, using a fluorescent intracellular calcium assay on
either rat hippocampal neurons or with human induced pluripotent stem cell-derived neurons (iCell neurons). This is,
presumably, due to the rapid desensitisation of a7 nAChR that is induced by orthosteric agonists. In contrast, clear agonist-
evoked responses were observed in fluorescence-based assays with the non-desensitising allosteric agonist 4BP-TQS and
also when compound B was co-applied with the non-desensitising positive allosteric modulator TQS. In summary, we have
demonstrated the suitability of subtype-selective orthosteric and allosteric ligands for the pharmacological identification
and characterisation of native nAChRs and the usefulness of ligands that minimise receptor desensitisation for the
characterisation of a7 nAChRs in fluorescence-based assays.
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Introduction
In common with other members of the Cys-loop family of
ligand-gated ion channels, nAChRs are pentameric neurotrans-
mitter receptors in which agonists and competitive antagonists
bind at a site located in the extracellular domain, at the interface of
two adjacent subunits [1]. However, in addition to this well-
characterised orthosteric binding site, nAChRs can be modulated
by the binding of ligands to distinct allosteric binding sites [2,3].
Indeed, modulation by allosteric ligands appears to be a feature
that is characteristic of ligand-gated ion channels [4]. In recent
years, a diverse array of nicotinic allosteric modulators have been
described [2,5], some of which have been reported to interact with
an intrasubunit transmembrane binding site [6–8].
A notable feature of a7 nAChRs is the rapid rate of receptor
desensitisation induced by conventional orthosteric agonists [9], a
phenomenon that is also influenced by temperature [10]. As is
now well established, the extent of a7 nAChR desensitisation can
also be influenced by allosteric modulators. Two types of positive
allosteric modulators (PAMs) of a7 nAChRs have been described:
those with minimal effects on receptor desensitisation (‘type I’
PAMs) and those that greatly reduce or abolish agonist-induced
desensitisation (‘type II’ PAMs) [2]. There is evidence that
compounds classified as being either type I or type II PAMs bind
competitively at a common or overlapping allosteric site on a7
nAChRs [11] and do so at a site in the receptor’s transmembrane
region [6,11]. It also seems likely that this classification is an over-
simplification because PAMs acting on a7 nAChRs with a wide-
spectrum of effects on receptor desensitisation have been reported
[8]. Additionally, there is evidence that ligands binding at this
allosteric transmembrane site on a7 nAChRs can result in receptor
activation in the absence of a conventional orthosteric agonist and
can cause activation that is associated with minimal levels of
receptor desensitisation [7,8]. Whereas allosteric modulators that
lack agonist activity have been described as PAMs, the term
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allosteric agonist has been used to describe ligands that bind to an
allosteric site but, unlike PAMs, have agonist activity in the
absence of an orthosteric agonist [7].
A major goal, both for academic research and for pharmaceu-
tical drug discovery is the identification and characterisation of
ligands that are selective for particular receptor subtypes. In the
case of a7 nicotinic acetylcholine receptors (nAChRs), interest in
subtype-selective agonists and allosteric modulators has arisen, at
least in part, as a consequence of these receptors having been
implicated in a range of neurological and psychiatric disorders
[5,12,13]. Here we describe studies conducted with three
pharmacologically distinct a7-selective nicotinic ligands: an
orthosteric agonist, a positive allosteric modulator and a non-
desensitising allosteric agonist. The main motivation for the
experiments described in the present study is to examine the
suitability of these three pharmacologically distinct types of ligand
for the characterisation of native nAChRs. In addition we have
undertaken studies with recombinant nAChRs to assess the
subtype-selectivity of these compounds.
A large number of a7-selective nAChR agonists have been
identified in recent years [14,15], but one that has been studied
extensively is the biarylcarboxamide compound (R)-N-(1-azabicy-
clo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) [16]. It
has been described in the scientific literature, somewhat inconsis-
tently, as either ‘compound A’ [17–20] or as ‘compound B’ [21–
24]. Here, we used the nomenclature ‘compound B’, the name
that was assigned first to this molecule in the scientific literature.
In addition to studies with the orthosteric agonist compound B,
we have also examined the pharmacological properties of two
allosteric modulators of a7 nAChRs: 4-(1-napthyl)-3a,4,5,9b-
tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (TQS)
[7,25] and 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopen-
ta[c]quinoline-8-sulfonamide (4BP-TQS) [7,8]. TQS has no
agonist activity on a7 nAChRs when applied alone but, as has
been reported previously, it is a potent PAM of a7 nAChRs [7,25].
Figure 1. Chemical structure of a7 nAChR orthosteric and allosteric ligands examined in the present study.
doi:10.1371/journal.pone.0055047.g001
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In addition to potentiating agonist-evoked responses when co-
applied with an orthosteric agonist, co-application of TQS also
greatly reduces the rate of desensitisation of a7 nAChRs [7,25]. As
explained above, this has resulted in it being described as a ‘type
II’ PAM [2,25]. 4BP-TQS has close chemical similarity to TQS
but acts as a potent allosteric agonist of a7 nAChRs, as has been
shown previously in studies conducted with recombinant receptors
expressed Xenopus laevis oocytes [7,8]. In contrast to orthosteric
agonists, activation of a7 nAChRs by 4BP-TQS is associated with
minimal levels of receptor desensitisation [7,8].
In this paper we have characterised, utilising recombinant
nAChRs receptors, the selectivity of compound B, TQS and 4BP-
TQS for a7 nAChRs. In addition, we describe studies examining
the suitability of these compounds for the pharmacological
characterisation of native nAChRs expressed in rat primary
hippocampal cell cultures and also in human iCell neurons.
Results
Subtype Selectivity of Compound B, TQS and 4BP-TQS
In previous studies the orthosteric agonist compound B
(Figure 1) has been described as being selective for a7 nAChRs
[17–19,21]. However, there is only a very limited amount of
published experimental data demonstrating that compound B
lacks agonist activity on nAChR subtypes other than a7. Here we
have examined the ability of compound B to activate several
human recombinant nAChR subtypes expressed in Xenopus
oocytes. Data obtained from these studies supports the conclusion
that compound B is an a7-selective agonist (Figure 2A). As is seen
with ACh, activation of human a7 nAChRs by compound B
results in rapid activation associated with fast desensitisation
(Figure 2A). However, compound B acted as a partial agonist:
maximal concentrations of compound B (30 mM) generating
responses that were 61610% (n = 6) of the responses with a
maximal concentration of ACh. In contrast, compound B had no
agonist activity on muscle (a1b1de) or neuronal (a3b4 or a4b2)
nAChRs (Figure 2A; Table 1).
TQS (Figure 1) has been shown previously to be a selective
positive allosteric modulator (PAM) of a7 nAChRs [25]. In
contrast, to its potentiating effects on a7 nAChRs, TQS has been
reported to cause inhibition of agonist-evoked responses with a3b4
and a4b2 nAChRs [25]. Our studies, conducted with human
recombinant a3b4 and a4b2 nAChRs expressed in Xenopus
oocytes (Figure 2B; Table 1), agree with this previously published
data, with particularly strong inhibition being observed with a3b4
nAChRs (Table 1). In addition, an inhibitory effect of TQS was
also observed on a1b1de muscle nAChRs (Figure 2B; Table 1).
More recently, it has been demonstrated that 4BP-TQS
(Figure 1), a compound with close chemical similarity to TQS, is
an allosteric agonist of a7 nAChRs [7,8]. In contrast to the rapid
rate of desensitisation observed when a7 nAChRs are activated by
orthosteric agonists such as ACh or compound B, little or no
desensitisation is observed in response to activation by 4BP-TQS
(Figure 2C). However, in previous studies, the selectivity of 4BP-
TQS for nAChR subtypes has not been examined. Here, we have
examined the ability of 4BP-TQS to activate a range of human
recombinant nAChRs expressed in Xenopus oocytes (Figure 2C).
4BP-TQS had no agonist activity on muscle (a1b1de) or neuronal
(a3b4 or a4b2) nAChRs (Figure 2C). In addition, as was observed
with TQS, co-application of 4BP-TQS caused inhibition of
responses to ACh on a3b4, a4b2 and a1b1de nAChRs (Table 1).
In summary, these data support the conclusion that compound
B, TQS and 4BP-TQS are selective agonists or potentiators of a7
nAChRs.
Figure 2. Subtype selectivity of compound B, TQS and 4BP-TQS
examined with human recombinant nAChR subtypes ex-
pressed in Xenopus oocytes. A) Responses to ACh (3 mM on a7
nAChRs and 100 mM on other nAChR subtypes; black bars) and to
compound B (30 mM; grey bars). B) Responses to ACh (100 mM) and to
ACh (100 mM; black bars) pre- and co-applied with TQS (100 mM; grey
bars). C) Responses to ACh (3 mM on a7 nAChRs and 100 mM on other
nAChR subtypes; black bars) and to 4BP-TQS (60 mM on a7 nAChRs and
100 mM on other nAChR subtypes; grey bars).
doi:10.1371/journal.pone.0055047.g002
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Characterisation of a7-selective Compounds on Native
a7 nAChRs by Patch-clamp Recording
The ability of compound B to activate native a7 nAChRs in rat
primary hippocampal neurons was examined by patch-clamp
recording (Figure 3). Rapidly desensitising dose-dependent
responses, characteristic of a7 nAChRs, were observed
(Figure 3A). Compound B activated rat hippocampal nAChRs
with an EC50 value of 4.561.1 mM (n = 4) and a Hill coefficient of
0.960.05 (n = 4) (Figure 3B). Responses to compound B in rat
primary hippocampal neurons were blocked by the a7-selective
nAChR antagonist methyllycaconitine (MLA) (Figure 3C).
Previous studies have shown that TQS is a strong potentiator of
recombinant a7 nAChRs, causing a dramatic reduction in
orthosteric agonist-induced receptor desensitisation [7,8,25]. The
ability of TQS to potentiate compound B-evoked currents was
examined in rat primary hippocampal neurons (Figure 4). When a
maximal concentration of TQS (10 mM) was pre-applied and then
co-applied with an EC20 concentration of compound B, responses
were potentiated by 5.261.8 fold (n = 6) (Figure 4A). When TQS
was co-applied with compound B, without a pre-application a two-
component response was observed (Figure 4B). As has been
suggested previously from studies with recombinant a7 nAChRs, it
is likely that this two-component response is due to a rapid
interaction of the orthosteric agonist with its extracellular binding
site, followed by a slower interaction of TQS with its transmem-
brane allosteric binding site [7].
Previous studies with recombinant nAChRs have demonstrated
that 4BP-TQS is a potent allosteric agonist that activates a7
nAChRs with minimal desensitisation [7,8]. We have now
examined native nAChRs expressed in rat hippocampal neurons
and observed a similarly dramatic difference in responses evoked
with the orthosteric agonist compound B and the allosteric agonist
4BP-TQS (Figure 5). Peak responses to a maximal concentration
of 4BP-TQS (30 mM) were 3.560.6 (n = 9) fold larger than
responses to a maximal concentration of compound B (30 mM). In
addition, as seen previously with recombinant a7 nAChRs [7,8]
responses to 4BP-TQS had a slower onset and resulted in a very
much slower rate of desensitisation than is observed with
orthosteric agonists (Figure 5A).
Another feature of both TQS and 4BP-TQS that has been
observed with recombinant nAChRs is their ability to facilitate
recovery of a7 nAChRs from desensitisation induced by
orthosteric agonists [7,8]. We here confirm that the same effect
can be seen by co-applying either TQS or 4BP-TQS to native
hippocampal nAChRs after desensitisation with compound B
(Figure 5B). After responses had fully desensitised in the continued
presence of compound B, recovery from desensitisation was
observed with both allosteric modulators (Figure 5B). Also, as
expected from previous studies with recombinant a7 nAChRs,
responses to 4BP-TQS were completely blocked by the a7-
selective antagonist MLA (Figure 5C).
Characterisation a7-selective Compounds on Native a7
nAChRs by Calcium Imaging
The suitability of compound B, TQS and 4BP-TQS as tools for
the pharmacological characterisation of endogenous nAChRs
expressed in primary rat hippocampal neurons was also examined
by fluorescence-based intracellular calcium imaging. We did not
detect an agonist-induced intracellular calcium response in
primary rat hippocampal neurons with compound B (Figure 6),
presumably because of the low open probability and rapid
desensitisation of a7 nAChRs in response to activation with
orthosteric agonists compared to that observed in the presence of
type II PAMs or allosteric agonists [26,27]. Similarly, and as
expected by a pure potentiator, no response was detected when
TQS was applied alone. In contrast, a strong dose-dependent
increase in intracellular calcium was observed when compound B
(5 nM) was co-applied with TQS (Figure 7A). Responses to the co-
application of compound B and TQS were observed in 5965% of
cells (n = 10) (Figure 6B) and experiments conducted with a range
of TQS concentrations revealed an EC50 value of 0.960.3 mM
(n = 3) (Figure 7A).
In contrast to the lack of effects on intracellular calcium
responses in primary hippocampal neurons with the orthosteric
agonist compound B, clear agonist-evoked responses were detected
with 4BP-TQS (Figure 6 and 7B) in 4164% of cells examined
(n = 31). 4BP-TQS activated native nAChRs with an EC50 value
of 5.561.8 mM and a Hill coefficient of 2.260.6 (n = 6; Figure 7B).
In addition, responses to 4BP-TQS were blocked completely by
the a7-selective antagonist MLA (Figure 7C). Antagonism by
MLA was dose-dependent, with an IC50 value of 0.7660.09 nM
(Data not shown). Studies conducted with a range of concentra-
tions of 4BP-TQS demonstrated that antagonism by MLA was not
surmountable (Figure 7C), consistent with previous evidence that
MLA and 4BP-TQS do not bind competitively at a common site
[7].
Responses evoked by 4BP-TQS (10 mM) were also blocked in a
dose-dependent manner by TQS with an IC50 value of
6.160.4 mM (n = 3; Figure 8). This is consistent with previous
studies indicating that TQS and 4BP-TQS bind competitively at a
common or overlapping allosteric site [7,8].
Table 1. Pharmacological properties of TQS and 4BP-TQS on nAChR subtypes.
Receptor subtype TQS 4BP-TQS
Fold potentiation* % Inhibition** Agonist response{ % Inhibition{{
a1b1de 2 2762 (n= 5) 2 2465 (n= 5)
a3b4 2 3763 (n= 4) 2 36610 (n=4)
a4b2 2 963 (n= 3) 2 964 (n= 3)
a7 2866 (n= 13) 2 3866 (n= 23) 2
*Fold potentiation of response to ACh (100 mM) by TQS (100 mM).
**Percentage inhibition of response to ACh (100 mM) by TQS (100 mM).
{Agonist response of 4BP-TQS (100 mM) expressed as a fold response normalised to maximal concentration of ACh (3 mM).
{{Percentage inhibition of response to ACh (100 mM) by 4BP-TQS (100 mM). Data are means 6 SEM.
doi:10.1371/journal.pone.0055047.t001
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Functional Characterisation of Native nAChRs in Human
iCell Neurons
The successful demonstration of functional nAChRs in primary
rat hippocampal neurons by calcium imaging, prompted us to
examine whether this technique could be used to determine
whether functional nAChRs are present in human induced
pluripotent stem cell-derived (iCell) neurons. Agonist-evoked
elevations in intracellular calcium were observed in response to
4BP-TQS and also when compound B was co-applied with TQS
(Figure 9). Responses to the co-application of compound B and
TQS were observed in 84611% of cells (n = 3) and to 4BP-TQS
in 6867% of cells (n = 3) (Figure 6C). In both cases, agonist-
evoked responses were blocked by MLA (Figure 9). Thus, the
combined use of iCell neurons and a7-selective allosteric
modulators provides a convenient approach to the rapid
fluorescence-based characterization of native human a7 nAChRs.
Discussion
Nicotinic receptors are important targets for pharmaceutical
drug discovery [14,15]. For example, nAChRs expressed at the
neuromuscular junction (a1b1de) are targets for muscle relaxant
drugs and nAChR subtypes in the brain (such as a4b2) are targets
for drugs used to aid smoking cessation. In addition, neuronal
nAChR subtypes such as a7 have been identified promising targets
for drug targets in a variety of neurological and psychiatric
disorders [12,28]. As a consequence, considerable efforts have
been focussed on the identification of compounds that are selective
for a7 nAChRs [5]. These include conventional orthosteric
agonists as well as allosteric modulators of a7 nAChRs that either
potentiate orthosteric agonists or are able to activate a7 nAChRs
via an allosteric site [5,12,28].
It is well-established that orthosteric agonists such as ACh bind
to an extracellular site at the interface between two subunits [29].
In contrast, there is evidence that PAMs such as TQS and
Figure 3. Agonist activation of a7 nAChRs by compound B
examined by patch-clamp in rat primary hippocampal cells. A)
Representative recordings showing responses to the application of
compound B (0.3 to 30 mM; black bars). B) Dose-response data are
presented for compound B (0.03 to 100 mM). Data are normalised to
30 mM compound B. Data are means 6 SEM of 5 independent
experiments. C) Responses to compound B (10 mM, black bars) were
blocked by the a7-selective antagonist methyllycaconitine (MLA; 10 nM,
grey bar).
doi:10.1371/journal.pone.0055047.g003
Figure 4. Positive allosteric modulation of a7 nAChRs by TQS
examined by patch-clamp in rat primary hippocampal cells. A)
Representative recordings showing responses to the application of
compound B (1 mM; Left; black bar) and of TQS (10 mM; grey bar) pre-
applied for 5 s and then co-applied with compound B (1 mM; Right;
black bar). B) Co-application of compound B (1 mM; black bar) with TQS
(10 mM; grey bar) results in a two-component response.
doi:10.1371/journal.pone.0055047.g004
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allosteric agonists such as 4BP-TQS bind at an intra-subunit site in
the nAChR transmembrane domain [6–8]. In addition to being
allosteric modulators of orthosteric agonists, PAMs such as TQS
block responses to allosteric agonists [8]. Experimental data and
computer docking simulations are consistent with these two classes
of allosteric modulator (PAMs and allosteric agonists) binding at a
common site [6,7] but it is possible that such effects could result
from TQS and 4BP-TQS binding to two distinct non-overlapping
allosteric sites.
Because of the extensive subunit diversity of nAChRs [30], it is
important to establish the subtype selectivity of such ligands. In
this study we have focussed on three previously described a7
nAChR ligands, an orthosteric agonist (compound B), a positive
allosteric modulator (TQS) and an allosteric agonist (4BP-TQS).
Studies conducted with recombinant nAChRs expressed in Xenopus
oocytes have enabled us to demonstrate that all three of these
ligands show a high degree of selectivity for a7 nAChRs (Figure 2).
The availability of subtype-selective ligands is particularly impor-
tant for the characterisation of native nAChRs, due to the
likelihood that neurons may express a heterogeneous mixture of
receptor subtypes of uncertain subunit composition [30,31]. In the
present study we have exploited the availability of a7-selective
ligands to characterise native a7 nAChRs. Initial studies,
conducted by patch-clamp electrophysiology demonstrated that
all three a7-selective ligands (compound B, TQS and 4BP-TQS)
exhibited properties on native a7 nAChRs similar to those
reported previously on recombinant receptors. In addition, these
studies have been extended to examine the suitability of these
compounds for fluorescence-based techniques. In part, the
rationale for these studies is the usefulness of fluorescence-based
assays for high-throughput studies aimed at receptor identification
and characterisation.
Patch-clamp studies conducted with rat hippocampal neuronal
neurons have confirmed the ability of TQS to potentiate native a7
nAChRs and to reduce the rapid rate of desensitisation induced by
orthosteric agonists (Figure 4A). In addition, for the first time, we
have demonstrated the ability of an allosteric agonist (4BP-TQS)
to activate native a7 nAChRs. As reported previously in studies
with recombinant a7 nAChRs [7], 4BP-TQS activated native
nAChRs in rat hippocampal cells without inducing the rapid
agonist-induced desensitisation seen with orthosteric agonists
(Figure 5A). Data obtained with native a7 nAChRs has also
confirmed the ability of both TQS and 4BP-TQS to reactivate
native a7 nAChRs after orthosteric agonist-induced desensitisation
(Figure 5B). All of these findings are consistent with previous
studies conducted with recombinant a7 nAChRs [7,8,25].
Due to the low open probability and rapid rate of desensitisation
of a7 nAChRs, conventional orthosteric agonists are not well
suited to fluorescence-based functional assays. However, previous
studies with recombinant a7 have demonstrated that a7 responses
can be detected in fluorescence-based assays when conventional
agonists are co-applied with potentiators that reduce rates of
receptor desensitisation [32–35]. Here we have demonstrated
similar effects with two cell types expressing native a7 nAChRs, rat
hippocampal neuronal cells and human induced pluripotent stem
cell-derived neurons. The identification of tools and techniques
suitable for detection, in fluorescence-based assays, of a7 nAChRs
expressed endogenously in cell preparations such as primary
hippocampal neurons and iCell neurons will be of considerable
assistance for both academic research and pharmaceutical drug
discovery.
Although there have been previous studies that have examined
the properties of a7 nAChRs PAMs on native nAChRs
[32,34,36,37], we are not aware of any such studies with a7
nAChR allosteric agonists. Our patch-clamp electrophysiological
studies reveal (Figures 4 and 5) that both TQS and 4BP-TQS
behave in a similar manner on native a7 nAChRs as they do on
recombinant a7 nAChRs [7,8,25]. Significantly, we have also
demonstrated that non-desensitising allosteric agonists, such as
4BP-TQS, enable a7 nAChRs expression and function to be
examined by fluorescence-based assays without the need for a
second potentiating ligand (Figure 6 and 7).
Figure 5. Characterisation of 4BP-TQS on a7 nAChRs examined
by patch-clamp recording of rat primary hippocampal cells. A)
Representative recordings showing responses to the application of
compound B (30 mM; Left; black bar) and of 4BP-TQS (30 mM; Right; grey
bar). B) Prolonged exposure of a7 nAChRs to compound B (1 mM; black
bar) results in receptor activation, followed by rapid desensitisation. In
continued presence of compound B (1 mM; black bar), co-application of
either TQS (1 mM; Left; grey bar) or 4BP-TQS (30 mM; Right; black bar)
resulted in reactivation of desensitised receptors. C) Responses to 4BP-
TQS (30 mM; Left; black bar) are blocked by MLA (10 nM; grey bar) when
MLA was pre-applied for 15 s and then co-applied with 4BP-TQS
(30 mM; black bar).
doi:10.1371/journal.pone.0055047.g005
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Historically, the very rapid desensitisation of a7 nAChRs caused
some controversy regarding the properties of these receptors. For
example, prior to the molecular cloning of a7, there were known
to be binding sites for the snake neurotoxin a-bungarotoxin in
both the mammalian brain and at the neuromuscular junction.
However, functional nAChRs, blocked by a-bungarotoxin, had
not been detected in the brain. This led to the suggestion that
brain a-bungarotoxin binding sites did not correspond to
functional nAChRs [27], an idea that persisted until the cloning
and functional characterization of recombinant a7 nAChRs [9].
The availability of ligands that activate a7 without inducing rapid
desensitisation has considerable potential benefits for the identi-
fication and characterisation of endogenous a7 nAChRs in native
cell preparations.
This study has confirmed the subtype selectivity of three
nAChR ligands that exhibit distinct pharmacological properties.
In addition, whereas previous studies reporting the effects of
allosteric agonists such as 4BP-TQS on a7 nAChRs have focussed
exclusively on recombinant receptors [7,8,10,27], here we have
confirmed that allosteric agonists display similar pharmacological
properties on native nAChRs to those reported previously on
recombinant receptors. We have also demonstrated that, whereas
orthosteric agonists of a7 nAChRs are not well-suited to
fluorescence-based assays, clear fluorescence responses can be
detected either by the use of an allosteric agonist (4BP-TQS) or by
the co-application of a type II PAM (TQS). Finally, by the
combined use of a non-desensitising subtype-selective allosteric
modulators and fluorescence-based calcium imaging techniques,
we have been able to demonstrate, for the first time, the expression
of a7 nAChRs in human induced pluripotent stem cell-derived
neurons. This is important, given the need in pharmaceutical drug
discovery to identify convenient sources of human native neuronal
nAChRs for compound screening and testing.
Figure 6. Characterisation of native nAChRs in rat primary hippocampal cells and human induced pluripotent stem cell-derived
neurons, examined by fluorescence-based intracellular calcium imaging. A) Pseudocolour images of rat hippocampal neurons
corresponding to low initial resting calcium levels (Left) and higher calcium levels, after application of 30 mM 4BP-TQS (Right). B) Single cell
traces (cyan) for all neurons present in the optical field. The average response is shown in red (n = 89 cells). C) Histogram illustrating the percentage of
cells that responded to compound B (1 mM), compound B co-applied with TQS (1 mM and 10 mM, respectively) and 4BP-TQS (30 mM) in rat primary
hippocampal cells (blue) and in iCell neurons (red). Data were normalised to the total number of cells that responded to KCl (50 mM) (n = 3–31).
doi:10.1371/journal.pone.0055047.g006
Figure 7. Characterisation of TQS and 4BP-TQS on a7 nAChRs
in rat primary hippocampal cells, examined by fluorescence-
based intracellular calcium imaging. A) Potentiation by TQS of
responses evoked by compound B. TQS was pre-applied and then co-
applied (0.3 mM, 3 mM, and 30 mM) with compound B (5 nM; Left). The
trace represents the average response of 66 individual traces 6 SEM.
Dose-response data are presented (Right) for a range of concentrations
of TQS (0.03 to 30 mM) in the presence of compound B (5 nM). B)
Calcium-responses in response to application of 4BP-TQS (1 and 30 mM)
(Left). The trace represents the average response of 89 individual traces
6 SEM. Dose response data are presented (Right) for a range of
concentrations of 4BP-TQS (0.3 to 30 mM). C) Responses to 4BP-TQS
(30 mM) were blocked by MLA (100 nM) when MLA was pre-applied and
then co-applied with 4BP-TQS (30 mM; Left). The trace represents the
average response of 106 individual traces 6 SEM. Dose response data
are presented for a range of concentrations of 4BP-TQS in the absence
(circles) or presence (squares) of MLA (0.7 nM). In all cases, MLA was
pre-applied for 30 s and then co-applied with 4BP-TQS. All responses
were normalised to KCl (50 mM). Dose-response data are means 6 SEM
of 3–7 independent experiments.
doi:10.1371/journal.pone.0055047.g007
Figure 8. Block of 4BP-TQS responses by TQS in rat primary
hippocampal cells examined by fluorescence-based intracellu-
lar calcium imaging. Dose response data are presented for a range of
concentrations of TQS (0.3 to 30 mM) in the presence of 4BP-TQS
(10 mM). In all cases TQS was pre-applied for 30 s and then co-applied
with 4BP-TQS. Responses were normalised to 4BP-TQS (10 mM). Data are
means 6 SEM of 3 independent experiments.
doi:10.1371/journal.pone.0055047.g008
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Materials and Methods
Chemical Synthesis
(R)-N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-car-
boxamide) (compound B) was synthesised by Lilly Research
Laboratories according to methods described previously [16]. 4-(1-
napthyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfon-
amide (TQS) and 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS) were obtained
from Chembridge Corporation (San Diego, CA).
Subunit cDNAs and Plasmid Expression Vectors
Human a3, a4, b2 and b4 nAChR subunit cDNAs [38] in the
plasmid pcDNA3.1 were obtained from Merck Research Labo-
ratories (La Jolla, CA). Human a7 nAChR subunit cDNA in the
plasmid pSP64GL has been described previously [7,39]. Human
a1, b1, d and e subunit cDNAs [40] in the plasmid pcDNA3.1
were kindly provided by David Beeson, University of Oxford.
Xenopus Oocyte Electrophysiology
Adult female Xenopus laevis frogs were obtained from the
European Xenopus Resource Centre (University of Portsmouth).
Xenopus laevis oocytes were isolated and defolliculated as described
previously [41] following procedures that have been approved by
both UCL’s Biological Services Management Group and the UK
Home Office (under licences PIL70/23585 and PPL70/06819).
To express human a7 nAChRs, in vitro transcribed cRNA was
injected into the oocyte cytoplasm. In vitro transcription of cRNA
was carried out using the mMESSAGE mMACHINE SP6
transcription kit (Ambion, Huntington, UK). Oocytes were
injected with 6–12 ng cRNA per oocyte in a volume of 32.2 nl
using a Drummond variable volume microinjector. To express
human a4b2 and a3b4 nAChRs, plasmid cDNA constructs were
co-injected into the oocyte nucleus in a 1:1 ratio, and approxi-
mately 10 ng of cDNA was injected in a total injection volume of
32.2 nl per oocyte. Two electrode voltage-clamp recordings were
performed (with the oocyte membrane potential held at 260 mV),
as described previously [41] using a Warner Instruments OC-
725C amplifier (Harvard Apparatus, Edenbridge, UK), PowerLab
8SP and Chart 5 software (AD Instruments, Oxford, UK).
Agonists and allosteric modulators were applied to oocytes using
a BPS-8 solenoid valve solution exchange system (ALA Scientific
Inc., Westbury, NY), controlled manually or by Chart software.
Cell Culture
Hippocampal tissue, isolated from E18 Sprague Dawley rat
brain, was purchased from Charles River Laboratories (Margate,
UK). Typically, 8–10 hippocampi were dissociated in 10 ml
trypsin-EDTA for 10 min at 37uC. The trypsin-EDTA solution
was replaced with 5 ml neurobasal medium (Invitrogen, Paisley,
UK) supplemented with 10% heat-inactivated foetal bovine serum
(FBS, PAA Laboratories GmbH), B-27 supplement (Invitrogen,
Paisley, UK) and 29.2 mg/ml L-glutamine (PAA Laboratories
GmbH). The neurobasal medium was then replaced with 2.5 ml
Hank’s balanced salt solution (HBSS, Invitrogen, Paisley, UK)
supplemented with 20 mg/ml DNase (Sigma-Aldrich, Poole, UK)
and gently triturated by suction using a 1 ml Gilson pipette. Once
the cells were dissociated, 7.5 ml HBSS with DNase was added
and centrifuged for 5 min at 5uC and 2006g (RCF). For patch-
Figure 9. Characterisation of TQS and 4BP-TQS in human
induced pluripotent stem cell-derived neurons examined by
fluorescence-based intracellular calcium imaging. A) Pre- and co-
application of TQS (30 mM) with compound B (30 nM) potentiates the
amplitude of compound B -evoked calcium-responses (almost unde-
tectable in the absence of TQS) (Left). The trace represents the average
response of 35 individual traces 6 SEM. Responses to compound B
(30 mM) co-applied with TQS (30 mM) are blocked when pre- and co-
applied with MLA (1 mM; Right). The trace represents the average
response of 137 individual traces 6 SEM. B) Agonist-evoked calcium-
responses were detectable in response to the allosteric agonist 4BP-TQS
(30 mM; Left). The trace represents the average response of 122
individual traces 6 SEM. Responses to 4BP-TQS (30 mM) were blocked
by pre- and co-application of MLA (1 mM; Right). The trace represents
the average response of 118 individual traces 56 SEM.
doi:10.1371/journal.pone.0055047.g009
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clamp experiments, dissociated cells were plated at a density of
approximately 16105 cells/ml (100 ml/cover slip) on Biocoat poly-
D-lysine (PDL)/laminin coverslips (Becton Dickinson Biosciences,
Oxford, UK). For Ca2+ imaging experiments, dissociated cells
were plated at a density of approximately 36104 cells/ml into
Biocoat PDL 96-well plates (100 ml/well).
Human neuronal cells, derived from induced pluripotent stem
cells (iCell neurons), were obtained from Cellular Dynamics
International (Madison, WI). Cells were plated at 36104 cells/ml
in Biocoat PDL 96-well plates (10 ml/well) and maintained at
37uC (5% CO2) in serum-free Neurobasal-B27 medium, as above.
Calcium imaging experiments were performed on these cells after
6–9 days in culture.
Patch-clamp Recording
Whole-cell voltage-clamp recordings were carried out 6–10 days
after plating. Cells selected for patch-clamp recordings had
somatic diameters of 15–30 mM, with neurite extensions. During
recordings, cells were continuously perfused in HEPES-buffered
Tyrode’s solution (HBTS, Invitrogen, Paisley, UK) containing
(mM): 135 NaCl, 5 KCl, 1.2 MgCl2, 2.5 CaCl2, 10 HEPES, 11
glucose, 0.001 tetrodotoxin (with citrate) (TTX), pH = 7.2 at room
temperature. Cells were voltage-clamped in the whole-cell
configuration (at holding potential of -60 mV) with an AxoPatch
200A patch-clamp amplifier (Molecular Devices, Sunnyvale, CA,
USA). Pipettes were pulled from borosilicate glass (Type GC150F-
10, Harvard Apparatus, Kent, UK) using a commercial puller
(Model P-87, Sutter Instruments, Novato, CA, USA) and had
resistances between 2 and 6 MV when filled with pipette solution
containing (mM): 1 MgCl2, 4 MgATP, 0.5 EGTA, 10 HEPES,
140 K gluconate (pH adjusted to 7.3 with KOH). Current data
was recorded at 10 kHz using a DA/AD interface (Digidata
1322A, Molecular Devices, Sunnyvale, CA, USA). Drugs were
applied using a multichannel perfusion system (Model BPS-8,
Scientifica, Uckfield, UK) positioned 150 mM away from the
recorded cell and controlled by Clampex 9 software (Molecular
Devices, Sunnyvale, CA, USA).
Fluorescence-based Intracellular Calcium Imaging
Fluorescence-based calcium imaging experiments were carried
out 6–10 days after plating of cells. Cells were loaded in the dark
for 60 min at room temperature (22uC), in HBTS (Invitrogen,
Paisley, UK) containing 4 mM of calcium-sensitive dye Fluo-4 AM
(Invitrogen,Paisley, UK) in the presence of 1% pluronic acid
(Invitrogen, Paisley, UK). Fluo-4 (Kd for Ca
2+= 345 nM) and
Fluo-4FF (Kd for Ca
2+= 9.7 mM) were used for experiments where
intracellular calcium responses were expected to be relatively weak
or strong, respectively. Cells were washed and continually perfused
during the experiment with HBTS containing (mM): 135 NaCl,
5 KCl, 1.2 MgCl2, 2.5 CaCl2, 10 HEPES, 11 glucose, 0.001
TTX, pH = 7.2. The perfusion flow rate was 3 ml/min, which
lead to complete replacement of the 100 ml volume in each well
every 2 seconds. Dye-loaded cells were viewed using an inverted
epifluorescence microscope (Axiovert,135TV, Zeiss, Cambridge,
UK). Fluo-4 fluorescence was excited by a 480610 nm light
source (Polychrome II, TILL-Photonics, Gra¨felfing, Germany) and
emission was captured by an iXon 897 EMCCD camera (Andor
Technologies, Belfast, UK) after passage through a dichroic mirror
(505LP nm) and a high pass barrier filter (515LP nm). Digitised
images were stored and processed by using Imaging Workbench
5.0 software (INDEC Biosystems, Santa Clara, CA, USA). Data
were analysed by averaging individual traces collected from a large
number of cells in multiple wells of the 96-well plate. Delta F/F0
values were measured by quantifying the ratio between the change
in fluorescence signal intensity (delta F) and baseline fluorescence
(F0).
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